Abstract
Over the years, research of nanoparticle applications in pre-clinical and clinical applications has greatly advanced our therapeutic and imaging approaches to many diseases, most notably neoplastic disorders. In particular, the innate properties of inorganic nanomaterials, such as gold and iron oxide, as well as carbon-based nanoparticles, have provided the greatest opportunities in cancer theranostics. Carbon nanoparticles can be used as carriers of biological agents to enhance the therapeutic index at a tumor site. Alternatively, they can also be combined with external stimuli, such as light, to induce irreversible physical damaging effects on cells. In this review, the recent advances in carbon nanoparticles and their use in cancer theranostics will be discussed. In addition, the set of evaluations that will be required during their transition from laboratory investigations toward clinical trials will be addressed.
Reference197 articles.
1. Drug delivery and nanoparticles: Applications and hazards;Borm;Int. J. Nanomed.,2008
2. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer;Green;Ann Oncol.,2006
3. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer;Miele;Int. J. Nanomed.,2009
4. Nanomedicine applications in the treatment of breast cancer: Current state of the art;Wu;Int. J. Nanomed.,2017
5. Nanoparticles in the clinic;Anselmo;Bioeng. Transl. Med.,2016